A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy

43Citations
Citations of this article
79Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in patients with localized osteosarcoma. Eligible patients received two courses of MAP chemotherapy before definitive surgery at week 10. Bevacizumab (15 mg/kg) was administered 3 days before starting chemotherapy then on day 1 of weeks 3 and 5 of chemotherapy. After surgery, patients received MAP for a total of 29 weeks; bevacizumab was added every 2 or 3 weeks on day 1 of chemotherapy at least 5 weeks after surgery. Group sequential monitoring rules were used to monitor for unacceptable bevacizumab-related targeted toxicity (grade 4 hypertension, proteinuria or bleeding, grade 3 or 4 thrombosis/embolism, and grade 2–4 major wound complications). Thirty-one patients (median age 12.8 years) with localized osteosarcoma were enrolled. No unacceptable targeted toxicities were observed except for wound complications (9 minor and 6 major), which occurred in 15 patients; none required removal of prosthetic hardware or amputation. The estimated 4-year event-free survival (EFS) rate and overall survival rate were 57.5 ± 10.0% and 83.4 ± 7.8%, respectively. Eight (28%) of 29 evaluable patients had good histologic response (<5% viable tumor) to preoperative chemotherapy. The addition of bevacizumab to MAP for localized osteosarcoma is feasible but frequent wound complications are encountered. The observed histologic response and EFS do not support further evaluation of bevacizumab in osteosarcoma.

References Powered by Scopus

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

5505Citations
N/AReaders
Get full text

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

2724Citations
N/AReaders
Get full text

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

1969Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The osteosarcoma microenvironment: A complex but targetable ecosystem

305Citations
N/AReaders
Get full text

Randomized phase II trial of bevacizumab or temsirolimus in combination with chemotherapy for first relapse rhabdomyosarcoma: A report from the Children's Oncology Group

87Citations
N/AReaders
Get full text

Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression

84Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Navid, F., Santana, V. M., Neel, M., McCarville, M. B., Shulkin, B. L., Wu, J., … Daw, N. C. (2017). A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. International Journal of Cancer, 141(7), 1469–1477. https://doi.org/10.1002/ijc.30841

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 23

68%

Professor / Associate Prof. 7

21%

Researcher 3

9%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 24

63%

Nursing and Health Professions 6

16%

Agricultural and Biological Sciences 4

11%

Biochemistry, Genetics and Molecular Bi... 4

11%

Article Metrics

Tooltip
Mentions
References: 2

Save time finding and organizing research with Mendeley

Sign up for free